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Abstract
Background: The nucleoside analog cladribine is used for the treatment of a variety of indolent
B- and T-cell lymphoid malignancies. The primary aim of the study was to evaluate the population
distribution of pharmacokinetic parameters in patients undergoing treatment with cladribine and
to detect the influence of different covariates on the pharmacokinetic parameters.
Methods:  This pharmacokinetic study presents the results of a retrospective population
pharmacokinetic analysis based on pooled data from 161 patients, who were given cladribine in
different administration routes in various dosing regimens. The plasma concentrations of cladribine
were determined by reversed-phase high-performance liquid chromatography using a solid phase
extraction with a limit of quantitation of 1 nM using 1 mL of plasma.
Results: A three compartment structural model best described the disposition of cladribine.
Clearance was found to be 39.3 L/hour, with a large interindividual variability. The half-life for the
terminal phase was 16 hours. Bioavailability was 100% and 35% for subcutaneous and oral
administration, respectively, with low interindividual variability. None of the investigated covariates
were found to be correlated with the pharmacokinetic parameters.
Conclusion: As interindividual variability in apparent clearance after oral administration was not
significantly higher compared to that following infusion, cladribine could be administered orally
instead of intravenously if compensated for its lower bioavailability. Individualized dosing on basis
of body surface area or weight does not represent an improvement in this study as compared to
administering a fixed dose to all patients.
Background
Cladribine [Leustatin®] is a purine analogue that entered
clinical testing fifteen years ago, with major activity in the
treatment of B- and T-cell lymphoid malignancies. Cladri-
bine has an outstanding therapeutic activity against hairy
cell leukemia, a disease in which the drug induces long-
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lasting complete remissions in the vast majority of
patients treated. The activity of cladribine has also been
demonstrated in chronic lymphocytic leukaemia (CLL)
non-Hodgkin's lymphoma, cutaneous T-cell lymphoma
and myeloid leukemia. Cladribine and the other newer
purine analogues are unique, when compared to tradi-
tional antimetabolites, in that they are equally cytotoxic
to both dividing and resting cells [1]. Cladribine is usually
administered at 0.09 mg/kg daily as a continuous intrave-
nous infusion over 7 days. However, pharmacokinetic
studies supporting the use of intermittent intravenous (iv)
infusions have shown a long terminal half-life of cladrib-
ine after a 2-hour infusion with the same anti tumour
activity seen with continuous iv infusion [2]. The pharma-
cokinetic profile of oral administration of cladribine
resembles that of a 2-hour iv infusion, with a bioavailabil-
ity of 37–51% [3,4]. Subcutaneous administration gives a
high peak concentration of short duration with an area
under the curve (AUC) identical to that of the iv infusion
and a bioavailability of 100%.
The primary aim of the study was to evaluate the popula-
tion distribution of pharmacokinetic parameters in
patients undergoing treatment with cladribine and to
detect the influence of different covariates on the pharma-
cokinetic parameters. This analysis was performed in
order to evaluate the plasma concentration-time profiles
in relation to previously presented pharmacokinetic data
and to elucidate the possibilities to create a better tailoring
of cladribine dosing.
Results
The population pharmacokinetic analysis of cladribine
was based on 1102 plasma concentrations obtained from
161 individuals. The observed plasma concentrations of
cladribine versus time are presented in Figure 1 and 2. The
initial runs carried out were aimed at finding a base model
(pharmacokinetic and statistical submodels). A three
compartment structural model best described the time
course of plasma concentrations of cladribine for all
patients and was therefore chosen for the present analysis.
The final disposition model is described as follows: a
three compartment model with interindividual variability
on clearance (CL), central and peripheral volumes of dis-
tribution (V1,  V2,  V3), intercompartmental clearances
(Q2, Q3), and with a proportional residual error model
for residual variability.
The final population parameter estimates based on the
model are given in Table 3. The clearance in the typical
patient was calculated to be 39.3 L/h, with relative stand-
ard error (RSE) of 4.9 % while the interindividual variabil-
ity, as expressed by the coefficient of variation, was 54%.
Diagnostic plots of the observed and population model
predicted concentrations after iv infusion, oral and subcu-
taneous administrations are shown in Figure 3A–C.
Observed plasma concentration versus time profile for  cladribine after a 2- hour iv infusion, oral and subcutaneous  administration once daily Figure 1
Observed plasma concentration versus time profile for 
cladribine after a 2- hour iv infusion, oral and subcutaneous 
administration once daily. Concentrations are given on a log-
arithmic scale.
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Observed plasma concentrations after repeated intravenous  administration (steady -state observations) Figure 2
Observed plasma concentrations after repeated intravenous 
administration (steady -state observations). Concentrations 
are given on a logarithmic scale.
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The oral data were best described with a first order absorp-
tion without lag time. The bioavailability was found to be
0.353 with RSE 7.9% and the interindividual variability
was estimated to be 4 % (expressed as coefficients of vari-
ation). The estimated value for the absorption rate con-
stant was 1.31 hour-1 with RSE 14%. As bioavailability
and interindividual variability in F were of particular
interest, some additional investigation was performed.
First, the 95% confidence interval for interindividual var-
iability in F was obtained using likelihood profiling. This
resulted in a 95 % confidence interval ranging from 0% to
10%. Second, in order to get a broader insight into the
first pass metabolism, bioavailability and variability in CL
following different administration routes, F was omitted
from the model and instead apparent CL and its interindi-
vidual variability was estimated separately for each route
of administration (other disposition parameters were still
estimated jointly). The estimated CL for the intravenous
route was 39.7 L/h (RSE 8%) while the estimates of the
oral CL (or rather CL/F) was 105 L/h (RSE 13%). The esti-
mated interindividual variability in CL for the intravenous
and oral routes were 59% (RSE 22%) and 55 (50%)
respectively. Third, a model allowing correlation between
F and CL was tested, but it did not result in any improve-
ments and variability in F was still not appreciable.
For the subcutaneous data the bioavailability was calcu-
lated to be close to 1 and therefore was fixed to this value,
as estimation of this parameter did not result with a signif-
icant model improvement. The corresponding result for
ka was 2.48 hour-1 with RSE 9.6%.
The terminal half-life was relatively long, 16 hours. The
half-life for the first distribution phase was calculated to
be 0.2 hour and the corresponding half-life for the second
distribution phase was 1.3 hours.
The highest and the lowest values for terminal half-life
were 58 hours and 5 hours respectively. The correspond-
ing accumulation index, the amount at steady state com-
pared to the corresponding value after the first dose at the
same time, was for the highest 3.05 and for the lowest
1.02.
None of the covariate relations, included in the general-
ised additive model, were found to be significant when
included in the NONMEM model.
Discussion
In this study we have evaluated pooled data from 161
patients at different centres, receiving different doses of
cladribine, administered by three different routes, using
different treatment schedules and leaving different
numbers of blood samples at different times. To perform
this evaluation we used nonlinear mixed effect modelling
Model predicted versus observed cladribine concentrations  after intravenous infusion (A), oral (B) and subcutaneous (C)  administration Figure 3
Model predicted versus observed cladribine concentrations 
after intravenous infusion (A), oral (B) and subcutaneous (C) 
administration. In the left panel predictions are based on the 
parameters of the typical individual whereas in the right panel 
predictions are based on individual parameter estimates. ID 
numbers has been used as plotting symbols and all observa-
tions for an individual are connected by a broken line. Con-
centrations are given on a logarithmic scale to facilitate 
model inspection.
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for the pharmacokinetic analysis of the data. A three com-
partment structural model best described the time course
of plasma concentrations of cladribine, which is also in
agreement with previously published individual pharma-
cokinetic modelling [4,5]. Cladribine, administered as an
oral solution, was rapidly absorbed and the absorption
was best described using a model with first order absorp-
tion without lagtime.
We calculated that the bioavailability after oral adminis-
tration of cladribine was 35.3% and this value is slightly
lower compared to the previous reports of 37–51%
[3,4,6,7]. The estimate of interindividual variability (IIV)
in oral bioavailability was surprisingly low, 4%. Only
seven patients had data following both intravenous and
oral administration and even if in theory, bioavailability
and variability in bioavailability can be estimated from a
parallel group study, the sparsity of crossover data might
be one explanation for the negligible value of variability
in bioavailability and a lower value for bioavailability.
Further, as all variability estimates are based on the nom-
inal dose being exact, deviations from this would inflate
variability in pharmacokinetic parameters. Therefore,
another possible explanation is that the apparent lack of
variability in F is due to that the variability between the
nominal and actual dose is larger for intravenous
administration than for oral administration. Variability
between nominal and exact dose will arise in the manu-
facturing process, but may also occur due to deviations
between nominal and actual volume infused and number
of tablets administered.
Last, estimates of variability in bioavailability obtained by
traditional non-compartmental methods are upwards
biased as any error in determining the AUC following
intravenous or oral administration will be translated into
an individual bioavailability estimate differing from the
true one. Thus, even a drug without variability in bioavail-
ability will appear to have variability when this is esti-
mated by classical two-stage methods. Nonlinear mixed
effects methods are in general showing less bias in
variability estimates than the classical two-stage methods
[8]. Many factors contribute to the bioavailability of
cladribine, but the low variability in bioavailability was
confirmed with classic pharmacokinetics (data not
shown), which is also in agreement with previous analy-
ses [3,4]. Consequently, the variability in AUC after oral
administration is of the same magnitude as after intrave-
nous administration, as the variability in CL is more pro-
nounced than that for the bioavailability Table 3.
To reach the general circulation, a drug given orally must
pass through the liver via the portal system. A shorter
onset and a more intense response may occur when giving
a compound orally, rather than as a 2-hour intravenous
infusion, if the compound is rapidly absorbed and under-
goes extensive first-pass conversion to an active metabo-
lite more potent than the parent. The metabolite of
cladribine, 2-chloroadenine, has 8 times lower cytotoxic
effect than cladribine, while five times more metabolite is
formed after an oral administration compared with after
an iv infusion [9].
After subcutaneous administration the bioavailability was
found to be 100% with a low interindividual variability
less than 1%. These results are in agreement with the pre-
vious analysis [3,7].
For the typical patient, 65 % of the elimination is associ-
ated with the terminal slope, 11% with the first and 24%
with the second slope. Although distribution kinetics can-
not be ignored, the majority of cladribine elimination is
clearly associated with events defined by the terminal
phase, which has a mean half-life of 16 hours.
It is standard practice in oncology to individualise chem-
otherapy dosing, and to dose according to BSA or weight,
with the aim of reducing the interpatient variability of
drug effect and toxicity. However, neither weight nor BSA
explains more than a minor part of the variability seen. In
this study, the modelling indicates that dosing according
to body weight or BSA does not represent any significant
improvement as compared to administration a fixed dose
to all patients. For a convincing evaluation of dosing
cladribine, more patients need to be studied, but the lack
of reduction in interindividual variability when entering
relationships with body size make it unlikely that body
size can explain more than a small portion of the interin-
dividual variability. Likewise, it has been shown that BSA
fails to standardize the marked interpatient variation in
pharmacokinetic variables for most cytotoxic drugs [10].
There is no simple satisfactory method for calculating
drug dose, and other non-BSA-based dose calculation
methods have been proposed and discussed [10-14].
Patients with a dose corrected for BSA or weight, but with
a low clearance, tend to have an excessive accumulation of
the drug and a high risk of toxicity. The amount at any
time within the dosing interval at plateau was maximum
3.05 times and minimum 1.02 times the values at the
corresponding times after a single dose. It seems therefore
valuable to adjust the dose according to pharmacody-
namic events such as observed toxicity, which is one
parameter used in non-BSA-based dose calculation meth-
ods to individualise treatment [10]. This is possible when
patients are treated with repeated courses, e.g. in low-
grade lymphomas, but not in the treatment of hairy cell
leukemia where only one course of treatment is given.BMC Pharmacology 2005, 5:4 http://www.biomedcentral.com/1471-2210/5/4
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Table 1: Descriptive statistics and distribution of diagnoses for patients initially included in the population pharmacokinetic analysis.
Gender m/f Age (years)2 Weight (kg)2 Height (cm)2 BSA1 (m2)2
Total 129/34 60 (13) [22–89] 76 (14) [48–118] 174 (9) [152–198] 1.9 (0.2) [1.5–2.4]
Diagnosis CLL HCL AML NHL CML LCH
Total 6 3 8 4 3742
1 body surface area
2 data is presented with mean (SD)
Abbreviations: CLL, chronic lymphocytic leukemia; HCH, hairy cell leukemia; AML, acute myeloic leukemia; NHL, non-Hodgkin's lymphoma; CML, 
chronic lymphocytic leukaemia; LCH, Langerhan's cell histiocytosis.
Table 2: Distribution of laboratory data for patients included in the population pharmacokinetic analysis
Mean SD Range Outliers
Creatinine clearance (mL/min) 81 27 5–162 5i, 16i, 27i, 161sc, 162i, o
S-aspartate aminotransferase (µkat/L) 0.52 0.44 0.07–4.4 1.9i, 2.1sc, 2.2i, 4.4i
S-alanine amintransferase (µkat/L) 0.49 0.5 0.08–5.3 1.6i, 2.0i, 2.1sc, 5.3i
S-alkaline phosphatase (µkat/L) 1.3 6.7 1.0–64 12i, 12i, 14sc, 54i, 64i
S-bilirubin (µmol/L) 14 25 3.0–284 41sc, 88i, 284i
Outliers were defined as: Creatinine clearance <30->150 (mL/min), aspartate aminotransferase >1.5 (µkat/L), alanine amintransferase >1.5 (µkat/L), 
alkaline phosphatase >10 (µkat/L), bilirubin >30 (µmol/L)
Abbreviations:i, infusion; o, oral; sc, subcutaneous
Table 3: Population pharmacokinetic parameter estimates for the typical individual after administration of cladribine as; an infusion, 
orally or subcutaneously. The relative standards errors are given in parentheses. The estimates of intersubject variability are given as 
coefficients of variation (%).
Parameter Population average Interindividual variability
Estimate (RSE%)1 Estimate % (RSE%)
Clearance (L/h) 39.3 (4.9) 54 (17)
V1 (L) 71.7 (13) 34 (62)
Q2 (L/h) 51.1 (6.8) 61 (17)
V2 (L) 475 (1.8) 70 (31)
Q3 (L/h) 105 (21) 61 (17)
V3 (L) 73.6 (13) 61 (17)
Oral Ka (h-1) 1.31 (14) 75 (50)
Oral F 0.353 (7.9) 4.1 (63)
Subcutaneous Ka (h-1) 2.48 (9,6) N.E.
Parameter Infusion (RSE %) Oral (RSE %) Subcutaneous (RSE %) IIV3 (RSE %)
Residual error2
Proportional 0.191 (8.2) 0.232(9.8) 0.162 (8.8) 24 (28)
1 Rellative standard error. given as %.
2 Residual error presented as population average of estimate and relative standard error in parentheses.
3 Interindividual variability in residual variability expressed as coefficient of variation
Abbreviations: CL, clearance from central compartment; V1, V2 and V3, central and peripheral volumes of distribution, Q2 and Q3, 
intercompartmental clearances; Ka, absorption rate constant (hour-1); F, bioavailability of drug; N.E., not estimatedBMC Pharmacology 2005, 5:4 http://www.biomedcentral.com/1471-2210/5/4
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The reasons why people differ in their responsiveness to
drugs are manifold. Age, weight, height, disease stage etc.
are important because they are sources of variability that
can be taken into account. None of the covariates
included in this study was found to have a significant
influence on the pharmacokinetics of cladribine. In this
study no patient with severe reduction of liver- or kidney
function was participating. Separate studies with such
patient groups are warranted.
Conclusion
As interindividual variability in apparent clearance after
oral administration was not significantly higher
compared to that following infusion, cladribine could be
administered orally instead of intravenously if compen-
sated for its lower bioavailability. Individualized dosing
on basis of body surface area or weight does not represent
an improvement in this study as compared to administer-
ing a fixed dose to all patients.
Methods
Patients
This population pharmacokinetic study is based on drug
concentration data from previously published
pharmacokinetic studies [2,3,5-7]. Patients from five cen-
tres in Sweden, Department of Oncology and Department
of Hematology at Karolinska Hospital in Stockholm,
Department of Medicine at Huddinge Hospital in Stock-
holm, Department of Hematology at Linköpings Hospital
in Linköping and one centre in the United Kingdom,
Taunton Hospital, Somerset, participated in these studies
after giving their informed consent. The study period,
from February 1990 to March 1996, included 215 patients
and 227 courses. Fifty-three courses in 52 patients were
excluded due to lack of information. Thus, 173 courses in
163 patients, (129 male, 34 female) with a mean age of 60
years (range 22–89) were initially included in population
analysis. However, during the analyses, one subject was
omitted as concentration time profile showed seven-fold
increase after ending the infusion and one subject was
excluded as an outlier in that the absorption was consid-
erably slower than for other individuals, possibly indicat-
ing another site of administration. Two courses were
excluded as drug was given in other administration route
(rectal) than the ones that are of interest for the current
analysis. Thus the final population analysis included 168
courses in 161 patients. More details regarding demo-
graphics and distribution of the different diagnoses
among patients are presented in Table 1. The intravenous
infusion results were based on 93 doses during 63 courses,
the subcutaneous results on 83 doses during 83 courses
and the oral results on 24 doses during 22 courses. For
seven patients observed concentrations following both
intravenous and oral administration was available. There
was no difference in demographic data between patients
included and not included in the analysis.
Drug administration
The trials, on which this study was based, had previously
been approved by the local Ethics Committee at the Karo-
linska Institute (Dnr 91:4, 91:190, 92:41, 93:62) and by
the Swedish Medical Product Agency.
The dose for the iv administration (2-hour infusion) was
5 mg/m2 or 0.12 mg/kg. The corresponding oral dose was
10 mg/m2 or 0.24 mg/kg administered in saline after over-
night fasting. No food was allowed until two hours after
dosage. The subcutaneous dose, 5 mg/m2 (2 mg/mL) was
given in the adipose tissue in the abdominal wall as an
injection. Six patients received a continuous iv infusion
for four to seven days, with a dose between 4.0–5.6 mg/
m2/24 hours. Three patients had a 2-hour iv infusion the
1st day and a continuous iv infusion the 2nd day with a
dose of 4.8–5.7 mg/m2. Dosing and sampling history was
collected including the dosing date and time, dose, and
treatment period.
The covariate data collected were gender, age at treatment,
body weight, body height, diagnosis and are summarized
in Table 1. Also laboratory data was included in the anal-
ysis, creatinine clearance according to Cockcroft-Gault
formula [15] presented kidney function, liver function
tests and lymphocyte count. There was no difference in
the laboratory data between the different routes of admin-
istration. The laboratory data for the mean patient pre-
sented with standard deviation and range are presented in
Table 2.
The lymphocyte count was for the mean patient with CLL
124(123) [3.2-472] × 109/L. CLL patient's response to
treatment was collected and was distributed as 32% com-
plete remission, 30% partial remission and 38% no remis-
sion in 73 patients. Staging according to Rai was 23%
stage 1, 27% stage 2, 19% stage 3 and 30% stage 4 and
staging according to Binet was 19% A, 33% B and 48% C.
Response, staging according to Rai and Binet were
included in the analysis of the 73 CLL patients. These data
were collected at the beginning of the treatment.
Blood sampling
Venous samples (10 mL) were collected from an indwell-
ing catheter into heparinized Venoject® tubes. The blood
was stored in ice water. The plasma was isolated within 6
hours after sampling and frozen immediately at -20°C.
The average patient had 8 (range 1–27) samples taken up
to 36 (range 3–303) hours.BMC Pharmacology 2005, 5:4 http://www.biomedcentral.com/1471-2210/5/4
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Determination of cladribine in plasma
The plasma concentrations of cladribine were determined
by reversed-phase high-performance liquid chromatogra-
phy using a solid phase extraction [2,16]. The limit of
quantitation was 1 nM for cladribine using 1 mL of
plasma, when determined cladribine at 265 nm.
Population pharmacokinetic analysis
Nonlinear mixed effect modelling was applied for the
pharmacokinetic analysis of the data using the software
NONMEM[17]. The program Xpose [18] was used for
data set checkout, exploration and visualisation, model
diagnostics, candidate covariate identification and model
comparison.
Structural pharmacokinetic model
The model building strategy involved a development of
an integrated model that simultaneously fit the data from
all administration routes. Thus, the estimates from this
model of the population disposition parameters and
interpatient variabilities are based on data from all
patients receiving cladribine by all administration routes.
Two- and three compartment disposition models were
evaluated for cladribine. A first-order absorption model,
characterized by the absorption rate constant (ka) with
estimated bioavailability (F) was used for extravascular
administration. The presence of a lag-time was investi-
gated for oral administration.
The analyses were made using the first order conditional
estimation method with interaction in NONMEM.
Statistical model
The interpatient variability for the parameters was
described using exponential models. Interpatient variabil-
ity was included on clearance (CL), central volume of dis-
tribution (V1), peripheral volumes of distribution (V2
and V3), intercompartmental clearance (Q2 and Q3),
absorption rate constant (ka) and bioavailability of drug
(F). Covariances between interpatient variabilities in dif-
ferent pharmacokinetic parameters were investigated.
Residual variability, which represents the composite influ-
ence of assay variability, patient compliance and model
misspecification, were described as a proportional com-
ponent with separate estimates for the different routes of
administration. The residual errors were assumed to be
symmetrically distributed. Further, it was assumed that
the residual error may not be constant across the individ-
uals since data were pooled from different centres and col-
lected over a long period of time. In order to handle such
a variation in the residual variability, the individual con-
tribution to the residual error was accounted for by
including an interpatient variability in the residual error
model [19].
Covariate model
The relationships between individual pharmacokinetic
parameters and covariates were explored using the soft-
ware Xpose and auxiliary program PsN [20]. The covariate
model was built in a stepwise fashion within the popula-
tion model, in which both linear and nonlinear relation-
ships between the pharmacokinetic parameters and
covariates were considered. The algorithm and assump-
tions have been described in detail elsewhere [21]. A gen-
eralised additive model was used to analyse the
relationship between covariates and preliminary individ-
ual parameter estimates [22]. This procedure, based on
the Akaike information criteria [23], will search for signif-
icant relationships between each of the parameters and
the candidate covariates. These models guided the inclu-
sion of covariates into the population model. The identi-
fied candidate covariates were evaluated in the base
model by testing each covariate individually on each
parameter and then by testing combinations of covariates
on the parameters. The P level for inclusion of a covariate
into the final population model was 0.01. This test was
based on the objective function value produced by NON-
MEM, which is minus twice the Log Likelihood value. The
difference in the objective function value between hierar-
chical models is approximately chi-squared distributed.
Model diagnostics and validation
Basic goodness of fit plots including population and indi-
vidual predictions versus observed concentrations, as well
as individual predictions versus individual weighted
residuals, were checked for diagnostic purposes. The pop-
ulation predictions are based on the typical population
parameters in the final population model, and the
individual predictions on the empirical Bayes estimates of
individual parameters.
Other calculations
The extent of accumulation following intravenous admin-
istration was obtained through model simulations and
was based on AUC following the first and a steady state
dosing interval.
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